Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Venetoclax; Rituximab · 1 trial · 2 indications
CR / VGPR 12 months after randomization
| Arm | Type | Description |
|---|---|---|
| Venetoclax / Rituximab | EXPERIMENTAL | Cycle 1 (28-days cycle) Stepwise dose escalation of Venetoclax in all patients with a target dose of xy mg/d QD PO. Day 1-7: Venetoclax xy mg/d QD PO Day 8-14: Venetoclax xy mg/d QD PO Day 15-28: Venetoclax xy mg/d QD PO Cycle 2-12: Day 1: Rituximab 375 mg/m2 IV Day 1-28: Venetoclax xy mg/d QD PO |
| Dexamethasone / Rituximab / Cyclophosphamide | ACTIVE_COMPARATOR | Cycle 1-6: Day 1: Dexamethasone 20 mg PO Day 1: Rituximab 375 mg/m2 IV Day 1-5: Cyclophosphamide 100 mg/m2 BID PO |
| Name | Type | Description |
|---|---|---|
| Venetoclax; Rituximab | DRUG | Combination of venetoclax and rituximab |
| DRC | DRUG | Combination of Dexamethasone / Rituximab / Cyclophosphamide |
Inclusion Criteria: * Proven clinicopathological diagnosis of WM as defined by consensus panel one of the Second International Workshop on WM (IWWM). Histopathology has to be perfomed before randomization but within the last 4 months before start of treatment. In addition, pathological specimens ha...
Venetoclax; Rituximab is being studied for the treatment of Waldenstrom Macroglobulinemia, specifically in treatment-naive patients. It is a combination therapy being evaluated in a Phase 2 clinical trial. The drug is intended for adult patients aged 18 years and older with this condition.
Venetoclax; Rituximab is being developed by AbbVie Inc. (ticker: ABBV). The company is conducting a Phase 2 clinical trial to evaluate the efficacy of this combination therapy in patients with Waldenstrom Macroglobulinemia.
Venetoclax; Rituximab is currently in Phase 2 clinical development. It is an investigational combination therapy being studied for Waldenstrom Macroglobulinemia. The drug has not been approved and is still undergoing clinical trials to assess its efficacy and safety.
Venetoclax; Rituximab is being evaluated in a Phase 2 clinical trial with the identifier NCT05099471. This trial is titled 'Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia' and is currently recruiting participants in Germany and Greece.
Venetoclax; Rituximab refers to the combination of venetoclax and rituximab used together in a single treatment regimen. The clinical trial NCT05099471 is studying this combination specifically for Waldenstrom Macroglobulinemia in treatment-naive patients.